Dr. Royal is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
12481 High Bluff Dr
Ste 200
San Diego, CA 92130Phone+1 858-436-1427Fax+1 858-436-1401
Education & Training
Allegheny Health Network Medical Education Consortium (AGH/WPH)Residency, Anesthesiology, 1990 - 1992
National Capital ConsortiumResidency, Internal Medicine, 1981 - 1984
University of Massachusetts Medical SchoolClass of 1981
Certifications & Licensure
FL State Medical License 2024 - 2027
CA State Medical License 2003 - 2026
NC State Medical License 2017 - 2020
PA State Medical License 1988 - 2006
OK State Medical License 1994 - 2003
MD State Medical License 1984 - 1991- American Board of Anesthesiology Anesthesiology
- American Board of Internal Medicine Internal Medicine
Clinical Trials
- Efficacy and Safety of Intravenous Acetaminophen Over 48 Hrs for the Treatment of Post-op Pain After Gynecologic Surgery Start of enrollment: 2006 Nov 01
Publications & Presentations
PubMed
- 85 citationsResearch design considerations for single-dose analgesic clinical trials in acute pain: IMMPACT recommendationsStephen A. Cooper, Paul J. Desjardins, Dennis C. Turk, Robert H. Dworkin, Nathaniel P. Katz
Pain. 2016-02-01 - 227 citationsDeveloping patient-reported outcome measures for pain clinical trials: IMMPACT recommendationsDennis C. Turk, Robert H. Dworkin, Laurie B. Burke, Richard Gershon, Rothman Ml
Pain. 2006-12-05 - 192 citationsCore outcome domains for chronic pain clinical trials: IMMPACT recommendations.Dennis C Turk, Robert H Dworkin, Robert R Allen, Nicholas Bellamy, Nancy Brandenburg
Pain. 2003-12-01
Press Mentions
Sorrento Therapeutics Inc. (NASDAQ: SRNE) Releases Preliminary Phase 2 Abivertinib Study Results for Hospitalized COVID-19 PatientsNovember 9th, 2021- Sorrento Therapeutics Inc. (NASDAQ: SRNE) Releases Preliminary Phase 2 Abivertinib Study Results for Hospitalized COVID-19 PatientsNovember 9th, 2021
- San Diego Therapeutics Company Battles COVID-19 VariantsMarch 9th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
